Description General description A cell-permeable, phenylbutyrate hydroxamate pan-HDAC inhibitor that is shown to suppress the activities of class I (HDAC1 and HDAC8), class II (HDAC4 and HDAC6), and class IV (HDAC11) HDACs by > ~90% compared to control, at a concentration of 1 µM with a comparable or greater inhibitory effect than SAHA. In vitro, this compound exhibits a broad spectrum of anti-tumor activities in NSCLC cells, holds synergistic effects with cisplatin in the reduction of cell viability, is implicated in the induction of the intrinsic apoptotic pathway, and displays inhibitory effects against mitosis and cytokinesis. This inhibitor is also shown to suppress tumor growth in mice genograft models by 62%, 78% and 90% at 7.5, 15 and 30 mg/kg respectively without adversely affect in body weight and detectable toxicity. Packaging 10 mg in Plastic ampoule Packaged under inert gas Warning Toxicity: Standard Handling (A) Reconstitution Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C. Other Notes Tang, Y., et al. 2010. PLoS One5, e12417.